Table 2.
Recommendations on vaccination against COVID-19 in patients with cancer.
| Population | Intention | Intervention | SoR | QoE | Reference |
|---|---|---|---|---|---|
| Cancer patients | Reduce rate of symptomatic COVID | Full vaccination against COVID | A | IIt | [139,140] |
| Cancer patients | Reduce rate of hospitalisation | Full vaccination against COVID | A | IIt | [139] |
| Cancer patients | Reduce mortality | Full vaccination against COVID | A | IIt | [139,140] |
| Cancer patients | Increase immunogenicity | Booster as recommended by national authorities | A | IIt | [39,41,45,[141], [142], [143]] |
| Cancer patients before start of therapy | Increase immunogenicity | Vaccinate before start of chemotherapy∗ | A | IIt | |
| Cancer patients due to receive other vaccination | Co-administration of needed vaccinations such as influenza | A | III | ||
| Cancer patients | Maintain immunogenicity | Pause cancer therapy | D | IIu | [144,145] |
| Cancer patients | Induce best possible vaccination response | Choose mRNA vaccines over all other vaccines | B | IIu | [145,146] |
| Cancer patients | Induce best possible vaccination response | Choose highest approved vaccine dose (no increased toxicity in patients with cancer) | B | IIu | [139,145,147] |
COVID, coronavirus; mRNA, messenger RNA; QoE, quality of evidence; SoR, strength of recommendation.